These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 18421845)

  • 1. [Clinical trials of renin-angiotensin antagonists in Japan].
    Nihon Yakurigaku Zasshi; 2008 Mar; 131(3):182-3. PubMed ID: 18421845
    [No Abstract]   [Full Text] [Related]  

  • 2. New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Weber MA
    Am J Cardiol; 2007 Aug; 100(3A):45J-52J. PubMed ID: 17666198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Debate concerning the optimal blockage of the renin-angiotensin system].
    Choukroun G
    Nephrol Ther; 2010 Jan; 6 Spec No 1():H1-9. PubMed ID: 20129454
    [No Abstract]   [Full Text] [Related]  

  • 4. RAAS inhibition/blockade in patients with cardiovascular disease: implications of recent large-scale randomised trials for clinical practice.
    Pitt B
    Heart; 2009 Aug; 95(15):1205-8. PubMed ID: 19401281
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
    Reboldi G; Angeli F; Cavallini C; Gentile G; Mancia G; Verdecchia P
    J Hypertens; 2008 Jul; 26(7):1282-9. PubMed ID: 18550998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Underuse of evidence-based therapies.
    Hlatky MA
    Circulation; 2004 Aug; 110(6):644-5. PubMed ID: 15302805
    [No Abstract]   [Full Text] [Related]  

  • 7. Angiotensin receptor blockers: novel role in high-risk patients.
    Javed U; Deedwania PC
    Cardiol Clin; 2008 Nov; 26(4):507-26. PubMed ID: 18929228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antihypertensive strategy based on angiotensin II receptor blockers: a new gateway to reduce risk in hypertension.
    Tocci G; Sciarretta S; Facciolo C; Volpe M
    Expert Rev Cardiovasc Ther; 2007 Jul; 5(4):767-76. PubMed ID: 17605654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ONTARGET still OFF-TARGET?
    Lambers Heerspink HJ; de Zeeuw D
    Circulation; 2011 Mar; 123(10):1049-51. PubMed ID: 21357820
    [No Abstract]   [Full Text] [Related]  

  • 10. Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers especially useful for cardiovascular protection?
    Ong HT
    J Am Board Fam Med; 2009; 22(6):686-97. PubMed ID: 19897698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the renin-angiotensin system in cardiovascular protection: Is it important to watch your C'ARB' intake?
    Strauss MH; Verma S
    Can J Cardiol; 2005 May; 21(7):577-80. PubMed ID: 15940355
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical studies on the blockade of the renin-angiotensin-aldosterone-system.
    Hennig L
    Clin Nephrol; 2003 Jul; 60 Suppl 1():S53-8. PubMed ID: 12940534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin receptor blockers and cardiovascular protection: are we ONTARGET?
    Ram CV; Deedwania PC
    Am J Cardiol; 2008 Nov; 102(9):1281-3. PubMed ID: 18940307
    [No Abstract]   [Full Text] [Related]  

  • 14. What is the role of angiotensin-receptor blockade in cardiovascular protection?
    Cohn JN
    Am Heart J; 2006 Nov; 152(5):859.e1-8. PubMed ID: 17070145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renin-angiotensin system modulation for treatment and prevention of cardiovascular diseases: toward an optimal therapeutic strategy.
    Giles TD
    Rev Cardiovasc Med; 2007; 8 Suppl 2():S14-21. PubMed ID: 17401312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors: where do we stand now?
    Böhm M
    Am J Cardiol; 2007 Aug; 100(3A):38J-44J. PubMed ID: 17666197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New therapeutic strategies with combined renin-angiotensin system inhibitors for pediatric nephropathy.
    Zaffanello M; Franchini M; Fanos V
    Pharmacotherapy; 2008 Jan; 28(1):125-30. PubMed ID: 18154482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectively targetting the renin-angiotensin-aldosterone system in cardiovascular and renal disease: rationale for using angiotensin II receptor blockers in combination with angiotensin-converting enzyme inhibitors.
    Weinberg MS; Weinberg AJ; Zappe DH
    J Renin Angiotensin Aldosterone Syst; 2000 Sep; 1(3):217-33. PubMed ID: 11881029
    [No Abstract]   [Full Text] [Related]  

  • 19. On target to dual block RAS?
    Papadopoulos DP; Papademetriou V; Makris TK
    Angiology; 2009 Dec-2010 Jan; 60(6):739-49. PubMed ID: 19144653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale for combining blockers of the renin-angiotensin system.
    Azizi M; Wuerzner G
    Semin Nephrol; 2007 Sep; 27(5):544-54. PubMed ID: 17868792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.